118 related articles for article (PubMed ID: 20846522)
21. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study.
Laaksonen DE; Niskanen L; Nyyssönen K; Punnonen K; Tuomainen TP; Salonen JT
Eur Heart J; 2005 Sep; 26(17):1783-9. PubMed ID: 15821003
[TBL] [Abstract][Full Text] [Related]
22. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
Hsiao PJ; Kuo KK; Shin SJ; Yang YH; Lin WY; Yang JF; Chiu CC; Chuang WL; Tsai TR; Yu ML
J Gastroenterol Hepatol; 2007 Dec; 22(12):2118-23. PubMed ID: 18031368
[TBL] [Abstract][Full Text] [Related]
23. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.
Del Ben M; Baratta F; Polimeni L; Angelico F
Intern Emerg Med; 2012 Oct; 7 Suppl 3():S291-6. PubMed ID: 23073870
[TBL] [Abstract][Full Text] [Related]
24. Serum C-reactive protein and risk of cardiovascular events in middle-aged and older chinese population.
Jiang S; Bao Y; Hou X; Fang Q; Wang C; Pan J; Zuo Y; Zhong W; Xiang K; Jia W
Am J Cardiol; 2009 Jun; 103(12):1727-31. PubMed ID: 19539083
[TBL] [Abstract][Full Text] [Related]
25. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
Eur Heart J; 2007 Jun; 28(11):1374-81. PubMed ID: 17242007
[TBL] [Abstract][Full Text] [Related]
26. C-reactive protein: an independent predictor of cardiovascular disease in Aboriginal Australians.
Wang Z; Hoy WE
Aust N Z J Public Health; 2010 Jul; 34 Suppl 1():S25-9. PubMed ID: 20618287
[TBL] [Abstract][Full Text] [Related]
27. [Non-alcoholic fatty liver disease: a new challenge for cardiologists].
Tarquini R; Lazzeri C; Boddi M; Marra F; Abbate R; Gensini GF
G Ital Cardiol (Rome); 2010 Sep; 11(9):660-9. PubMed ID: 21348181
[TBL] [Abstract][Full Text] [Related]
28. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes.
Narasimhan S; Gokulakrishnan K; Sampathkumar R; Farooq S; Ravikumar R; Mohan V; Balasubramanyam M
Clin Biochem; 2010 Jul; 43(10-11):815-21. PubMed ID: 20398645
[TBL] [Abstract][Full Text] [Related]
29. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.
Wilson PW; Nam BH; Pencina M; D'Agostino RB; Benjamin EJ; O'Donnell CJ
Arch Intern Med; 2005 Nov; 165(21):2473-8. PubMed ID: 16314543
[TBL] [Abstract][Full Text] [Related]
31. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
[TBL] [Abstract][Full Text] [Related]
32. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease.
Gulsen M; Yesilova Z; Bagci S; Uygun A; Ozcan A; Ercin CN; Erdil A; Sanisoglu SY; Cakir E; Ates Y; Erbil MK; Karaeren N; Dagalp K
J Gastroenterol Hepatol; 2005 Sep; 20(9):1448-55. PubMed ID: 16105135
[TBL] [Abstract][Full Text] [Related]
33. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.
Targher G; Bertolini L; Rodella S; Lippi G; Franchini M; Zoppini G; Muggeo M; Day CP
Obesity (Silver Spring); 2008 Jun; 16(6):1394-9. PubMed ID: 18369343
[TBL] [Abstract][Full Text] [Related]
34. Association among C-reactive protein, Fatty liver disease, and cardiovascular risk.
Lizardi-Cervera J; Chavez-Tapia NC; Pérez-Bautista O; Ramos MH; Uribe M
Dig Dis Sci; 2007 Sep; 52(9):2375-9. PubMed ID: 17458697
[TBL] [Abstract][Full Text] [Related]
35. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
[TBL] [Abstract][Full Text] [Related]
36. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors.
Loria P; Lonardo A; Lombardini S; Carulli L; Verrone A; Ganazzi D; Rudilosso A; D'Amico R; Bertolotti M; Carulli N
J Gastroenterol Hepatol; 2005 Aug; 20(8):1176-84. PubMed ID: 16048564
[TBL] [Abstract][Full Text] [Related]
37. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients.
Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L
J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
Loria P; Lonardo A; Bellentani S; Day CP; Marchesini G; Carulli N
Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
[TBL] [Abstract][Full Text] [Related]
39. NASH and cardiovascular biomarkers.
Ercin CN; Dogru T; Tasci I; Erdem G; Sonmez A; Tapan S
Obesity (Silver Spring); 2009 Apr; 17(4):627; author reply 627. PubMed ID: 19322144
[No Abstract] [Full Text] [Related]
40. Plasma free fatty acid patterns and their relationship with CVD risk in a male middle-aged population.
Skidmore PM; Woodside JV; Mc Master C; Bingham A; Mercer C; Evans A; Young IS; Yarnell JW
Eur J Clin Nutr; 2010 Mar; 64(3):239-44. PubMed ID: 20087373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
